MX337059B - Metodos y composiciones para modular la hemostasia. - Google Patents
Metodos y composiciones para modular la hemostasia.Info
- Publication number
- MX337059B MX337059B MX2012006837A MX2012006837A MX337059B MX 337059 B MX337059 B MX 337059B MX 2012006837 A MX2012006837 A MX 2012006837A MX 2012006837 A MX2012006837 A MX 2012006837A MX 337059 B MX337059 B MX 337059B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hemostasia
- modulate
- compositions
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a una variante del Factor Xa que modula la hemostasis que comprende al menos una mutación por substitución den los aminoácidos 41-179 y 235-488 de SEQ ID NO: 1, en donde la Val en la posición 236 se sustituye con un aminoácido en la posición 235 no es Val o Ala.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73668005P | 2005-11-15 | 2005-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX337059B true MX337059B (es) | 2016-02-09 |
Family
ID=38049397
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008006313A MX2008006313A (es) | 2005-11-15 | 2006-03-21 | Metodos y composiciones para modular la hemostasia. |
MX2012006836A MX336958B (es) | 2005-11-15 | 2006-03-21 | Metodos y composiciones para modular la hemostasia. |
MX2012006837A MX337059B (es) | 2005-11-15 | 2008-05-15 | Metodos y composiciones para modular la hemostasia. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008006313A MX2008006313A (es) | 2005-11-15 | 2006-03-21 | Metodos y composiciones para modular la hemostasia. |
MX2012006836A MX336958B (es) | 2005-11-15 | 2006-03-21 | Metodos y composiciones para modular la hemostasia. |
Country Status (26)
Country | Link |
---|---|
US (4) | US8383386B2 (es) |
EP (4) | EP2423224B1 (es) |
JP (4) | JP5823088B2 (es) |
KR (4) | KR101827569B1 (es) |
CN (1) | CN101356192B (es) |
AU (1) | AU2006315175B2 (es) |
BR (1) | BRPI0618654B1 (es) |
CA (2) | CA2971971A1 (es) |
CR (1) | CR9956A (es) |
DK (1) | DK1948690T3 (es) |
EC (1) | ECSP088452A (es) |
ES (2) | ES2496567T3 (es) |
GT (1) | GT200800065A (es) |
HK (2) | HK1128699A1 (es) |
IL (1) | IL191310A (es) |
MX (3) | MX2008006313A (es) |
MY (1) | MY162181A (es) |
NO (3) | NO345177B1 (es) |
NZ (1) | NZ568108A (es) |
PL (1) | PL1948690T3 (es) |
PT (1) | PT1948690E (es) |
RU (2) | RU2008123398A (es) |
SI (1) | SI1948690T1 (es) |
SV (1) | SV2008002906A (es) |
WO (1) | WO2007059513A2 (es) |
ZA (1) | ZA200804026B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268783B2 (en) | 2007-09-28 | 2012-09-18 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same |
SG185263A1 (en) | 2007-09-28 | 2012-11-29 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same |
US8455439B2 (en) | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
CN102625712B (zh) | 2009-07-15 | 2017-07-25 | 博尔托拉制药公司 | 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法 |
WO2012045569A1 (en) | 2010-10-06 | 2012-04-12 | Medimmune Limited | Factor ii and fibrinogen for treatment of haemostatic disorders |
CA2850603C (en) * | 2011-09-30 | 2021-11-16 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
MX365612B (es) * | 2012-07-25 | 2019-06-07 | Catalyst Biosciences Inc | Polipeptidos de factor x modificados y usos de los mismos. |
WO2014118677A1 (en) | 2013-01-31 | 2014-08-07 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
FR3001729B1 (fr) * | 2013-02-04 | 2015-03-06 | Lab Francais Du Fractionnement | Mutants du facteur x |
KR101988705B1 (ko) | 2013-09-24 | 2019-06-12 | 화이자 인코포레이티드 | 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물 |
US20160235824A1 (en) * | 2013-11-01 | 2016-08-18 | The Children's Hospital Philadelphia | Compositions and Methods for Increasing the Half-Life of Factor XA |
CA2937418A1 (en) | 2014-01-24 | 2015-07-30 | Pfizer Inc. | Compositions and methods for treating intracerebral hemorrhage |
PT3149163T (pt) * | 2014-05-26 | 2020-09-03 | Academisch Ziekenhuis Leiden | Proteínas proemostáticas para o tratamento de hemorragia |
US10676731B2 (en) | 2014-08-19 | 2020-06-09 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor IX function |
CN109789181A (zh) | 2016-07-27 | 2019-05-21 | 费城儿童医院 | 用于调节因子ix功能的组合物和方法 |
WO2023118150A1 (en) | 2021-12-22 | 2023-06-29 | Royal College Of Surgeons In Ireland | A conjugate for use in localising a molecule to the vascular endothelium. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093699A (en) | 1987-07-09 | 2000-07-25 | The University Of Manitoba | Method for gene therapy involving suppression of an immune response |
WO1994017810A1 (en) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
WO1994023744A1 (en) | 1993-04-16 | 1994-10-27 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
AU7676894A (en) | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
AT401270B (de) | 1994-09-26 | 1996-07-25 | Immuno Ag | Verfahren zur quantifizierung von genomischer dna |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
CN100569297C (zh) | 1995-02-28 | 2009-12-16 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
WO1997032481A1 (en) | 1996-03-07 | 1997-09-12 | The Regents Of The University Of California | Helper-free, totally defective adenovirus for gene therapy |
AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
AT405516B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
AT410216B (de) * | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
WO2001070763A1 (en) * | 2000-03-22 | 2001-09-27 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
FR2841904B1 (fr) * | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
CN102325880B (zh) * | 2008-12-19 | 2014-10-01 | 国家健康与医学研究院 | 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途 |
-
2006
- 2006-03-21 MX MX2008006313A patent/MX2008006313A/es active IP Right Grant
- 2006-03-21 MX MX2012006836A patent/MX336958B/es unknown
- 2006-11-15 EP EP11182949.5A patent/EP2423224B1/en active Active
- 2006-11-15 BR BRPI0618654-8A patent/BRPI0618654B1/pt active IP Right Grant
- 2006-11-15 DK DK06846312.4T patent/DK1948690T3/da active
- 2006-11-15 KR KR1020087014386A patent/KR101827569B1/ko active IP Right Grant
- 2006-11-15 MY MYPI20081594A patent/MY162181A/en unknown
- 2006-11-15 US US12/093,783 patent/US8383386B2/en active Active
- 2006-11-15 PT PT68463124T patent/PT1948690E/pt unknown
- 2006-11-15 JP JP2008541467A patent/JP5823088B2/ja active Active
- 2006-11-15 NZ NZ568108A patent/NZ568108A/en unknown
- 2006-11-15 KR KR1020147023791A patent/KR101574042B1/ko active IP Right Grant
- 2006-11-15 EP EP06846312.4A patent/EP1948690B1/en active Active
- 2006-11-15 CN CN2006800507791A patent/CN101356192B/zh active Active
- 2006-11-15 WO PCT/US2006/060927 patent/WO2007059513A2/en active Application Filing
- 2006-11-15 EP EP11182950.3A patent/EP2431390B1/en active Active
- 2006-11-15 KR KR1020137033906A patent/KR101600158B1/ko active Application Filing
- 2006-11-15 PL PL06846312T patent/PL1948690T3/pl unknown
- 2006-11-15 ES ES06846312.4T patent/ES2496567T3/es active Active
- 2006-11-15 CA CA2971971A patent/CA2971971A1/en not_active Abandoned
- 2006-11-15 KR KR1020167004589A patent/KR20160029135A/ko not_active Application Discontinuation
- 2006-11-15 ES ES11182949.5T patent/ES2549929T3/es active Active
- 2006-11-15 SI SI200631810T patent/SI1948690T1/sl unknown
- 2006-11-15 AU AU2006315175A patent/AU2006315175B2/en active Active
- 2006-11-15 CA CA2629491A patent/CA2629491C/en active Active
- 2006-11-15 RU RU2008123398/13A patent/RU2008123398A/ru not_active Application Discontinuation
- 2006-11-15 EP EP11182946A patent/EP2431389A1/en not_active Withdrawn
-
2008
- 2008-05-07 CR CR9956A patent/CR9956A/es unknown
- 2008-05-07 IL IL191310A patent/IL191310A/en active IP Right Grant
- 2008-05-12 ZA ZA200804026A patent/ZA200804026B/xx unknown
- 2008-05-13 NO NO20082182A patent/NO345177B1/no unknown
- 2008-05-14 GT GT200800065A patent/GT200800065A/es unknown
- 2008-05-15 SV SV2008002906A patent/SV2008002906A/es not_active Application Discontinuation
- 2008-05-15 MX MX2012006837A patent/MX337059B/es unknown
- 2008-05-15 EC EC2008008452A patent/ECSP088452A/es unknown
-
2009
- 2009-07-17 HK HK09106536.9A patent/HK1128699A1/xx unknown
-
2011
- 2011-07-25 RU RU2011130932/10A patent/RU2570547C2/ru active
-
2012
- 2012-06-21 HK HK12106113.5A patent/HK1165444A1/zh not_active IP Right Cessation
- 2012-12-23 US US13/726,187 patent/US9410137B2/en active Active
-
2013
- 2013-11-14 JP JP2013236348A patent/JP5957167B2/ja active Active
-
2015
- 2015-07-17 JP JP2015143337A patent/JP6236194B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-05 US US15/229,922 patent/US9896676B2/en active Active
-
2017
- 2017-09-04 JP JP2017169887A patent/JP6571735B2/ja active Active
-
2018
- 2018-02-20 US US15/899,609 patent/US20180251745A1/en not_active Abandoned
-
2020
- 2020-06-05 NO NO20200671A patent/NO20200671A1/no unknown
- 2020-06-05 NO NO20200670A patent/NO20200670A1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX337059B (es) | Metodos y composiciones para modular la hemostasia. | |
CY1117833T1 (el) | Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου | |
CY1113102T1 (el) | Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων | |
CR10213A (es) | Moduladores de la proteína quinasa aurora | |
CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
NO20092637L (no) | Fremgangsmater for behandling | |
CY2014030I1 (el) | Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate | |
DE602005021894D1 (de) | Triazolophthalazine | |
EA201070519A1 (ru) | Соединения тропана | |
CR11373A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA | |
CY2014011I1 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
EA200802008A1 (ru) | Фармацевтические композиции | |
EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
EA201100037A1 (ru) | Органические соединения | |
ECSP088558A (es) | Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa | |
SV2009003434A (es) | Inhibicion de arni de expresion de alfa-enac | |
CL2008000873A1 (es) | Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis. | |
JP2006122056A5 (ja) | β-グルカンの使用 | |
UY29853A1 (es) | Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas- | |
BRPI0813000A2 (pt) | Composições terapêuticas e uso das mesmas | |
UY31484A1 (es) | Piperidinas heteroaril-sustituidas | |
BRPI0720211A2 (pt) | Derivado de indanona, composição, e, uso de uma composição | |
CR11423A (es) | NUEVOS INHIBIDORES DE sEH Y SU USO | |
EA200870515A1 (ru) | Моноциклические гетероарильные соединения | |
EA200700400A1 (ru) | Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии |